<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35416707</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1098-5522</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>90</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>19</Day>
            </PubDate>
          </JournalIssue>
          <Title>Infection and immunity</Title>
          <ISOAbbreviation>Infect Immun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Role of NK-Like CD8<sup>+</sup> T Cells during Asymptomatic Borrelia burgdorferi Infection.</ArticleTitle>
        <Pagination>
          <StartPage>e0055521</StartPage>
          <MedlinePgn>e0055521</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e00555-21</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1128/iai.00555-21</ELocationID>
        <Abstract>
          <AbstractText>Lyme disease (LD) due to Borrelia burgdorferi is the most prevalent vector-borne disease in the United States. There is a poor understanding of how immunity contributes to bacterial control, pathology, or both during LD. Dogs in an area of endemicity were screened for B. burgdorferi and <i>Anaplasma</i> exposure and stratified according to seropositivity, presence of LD symptoms, and doxycycline treatment. Significantly elevated serum interleukin-21 (IL-21) and increased circulating CD3<sup>+</sup> CD94<sup>+</sup> lymphocytes with an NK-like CD8<sup>+</sup> T cell phenotype were predominant in asymptomatic dogs exposed to B. burgdorferi. Both CD94<sup>+</sup> T cells and CD3<sup>-</sup> CD94<sup>+</sup> lymphocytes, corresponding to NK cells, from symptomatic dogs expressed gamma interferon (IFN-γ) at a 3-fold-higher frequency upon stimulation with B. burgdorferi than the same subset among endemic controls. Surface expression of activating receptor NKp46 was reduced on CD94<sup>+</sup> T cells from LD, compared to cells after doxycycline treatment. A higher frequency of NKp46-expressing CD94<sup>+</sup> T cells correlated with significantly increased peripheral blood mononuclear cell (PBMC) cytotoxic activity via calcein release assay. PBMCs from dogs with symptomatic LD showed significantly reduced killing ability compared with endemic control PBMCs. An elevated NK-like CD8<sup>+</sup> T cell response was associated with protection against development of clinical LD, while excess IFN-γ was associated with clinical disease.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Scorza</LastName>
            <ForeName>Breanna M</ForeName>
            <Initials>BM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology, University of Iowagrid.214572.7, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mahachi</LastName>
            <ForeName>Kurayi G</ForeName>
            <Initials>KG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology, University of Iowagrid.214572.7, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cox</LastName>
            <ForeName>Arin D</ForeName>
            <Initials>AD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology, University of Iowagrid.214572.7, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Toepp</LastName>
            <ForeName>Angela J</ForeName>
            <Initials>AJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology, University of Iowagrid.214572.7, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pessoa-Pereira</LastName>
            <ForeName>Danielle</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology, University of Iowagrid.214572.7, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tyrrell</LastName>
            <ForeName>Phyllis</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>IDEXX Laboratories, Inc., Westbrook, Maine, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Buch</LastName>
            <ForeName>Jesse</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>IDEXX Laboratories, Inc., Westbrook, Maine, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Foltz</LastName>
            <ForeName>Jennifer A</ForeName>
            <Initials>JA</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Nationwide Children's Hospital, Columbus, Ohio, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Dean</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Nationwide Children's Hospital, Columbus, Ohio, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Petersen</LastName>
            <ForeName>Christine A</ForeName>
            <Initials>CA</Initials>
            <Identifier Source="ORCID">0000-0002-7285-4254</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology, University of Iowagrid.214572.7, Iowa City, Iowa, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 CA086862</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 AI007260</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 AI007260</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Infect Immun</MedlineTA>
        <NlmUniqueID>0246127</NlmUniqueID>
        <ISSNLinking>0019-9567</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>82115-62-6</RegistryNumber>
          <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>N12000U13O</RegistryNumber>
          <NameOfSubstance UI="D004318">Doxycycline</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D025065" MajorTopicYN="Y">Borrelia burgdorferi</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004318" MajorTopicYN="N">Doxycycline</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008193" MajorTopicYN="Y">Lyme Disease</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Borrelia burgdorferi</Keyword>
        <Keyword MajorTopicYN="N">Lyme disease</Keyword>
        <Keyword MajorTopicYN="N">NK cells</Keyword>
        <Keyword MajorTopicYN="N">NK-like CD8+ T cells</Keyword>
        <Keyword MajorTopicYN="N">NK-like cells</Keyword>
        <Keyword MajorTopicYN="N">tick-borne</Keyword>
        <Keyword MajorTopicYN="N">zoonotic</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare a conflict of interest. Jennifer A. Foltz has pending patents (WO 2019/152387, US 63/018,108) unrelated to the present work that are licensed to Kiadis, and a monoclonal antibody related to the present work licensed to EMD Millipore. The authors have no other conflicts of interest to disclose.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>13</Day>
          <Hour>12</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35416707</ArticleId>
        <ArticleId IdType="pmc">PMC9119074</ArticleId>
        <ArticleId IdType="doi">10.1128/iai.00555-21</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Nelson CA, Saha S, Kugeler KJ, Delorey MJ, Shankar MB, Hinckley AF, Mead PS. 2015. Incidence of clinician-diagnosed Lyme disease, United States, 2005–2010. Emerg Infect Dis
21:1625–1631. 10.3201/eid2109.150417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3201/eid2109.150417</ArticleId>
            <ArticleId IdType="pmc">PMC4550147</ArticleId>
            <ArticleId IdType="pubmed">26291194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kugeler KJ, Schwartz AM, Delorey MJ, Mead PS, Hinckley AF. 2021. Estimating the frequency of Lyme disease diagnoses, United States, 2010–2018. Emerg Infect Dis
27:616–619. 10.3201/eid2702.202731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3201/eid2702.202731</ArticleId>
            <ArticleId IdType="pmc">PMC7853543</ArticleId>
            <ArticleId IdType="pubmed">33496229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eisen RJ, Eisen L. 2018. The blacklegged tick, Ixodes scapularis: an increasing public health concern. Trends Parasitol
34:295–309. 10.1016/j.pt.2017.12.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pt.2017.12.006</ArticleId>
            <ArticleId IdType="pmc">PMC5879012</ArticleId>
            <ArticleId IdType="pubmed">29336985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steere AC, Strle F, Wormser GP, Hu LT, Branda JA, Hovius JWR, Li X, Mead PS. 2016. Lyme borreliosis. Nat Rev Dis Primers
2:16090. 10.1038/nrdp.2016.90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrdp.2016.90</ArticleId>
            <ArticleId IdType="pmc">PMC5539539</ArticleId>
            <ArticleId IdType="pubmed">27976670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Littman MP, Goldstein RE, Labato MA, Lappin MR, Moore GE. 2006. ACVIM small animal consensus statement on Lyme disease in dogs: diagnosis, treatment, and prevention. J Vet Intern Med
20:422–434. 10.1111/j.1939-1676.2006.tb02880.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1939-1676.2006.tb02880.x</ArticleId>
            <ArticleId IdType="pubmed">16594606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee W-Y, Sanz M-J, Wong CHY, Hardy P-O, Salman-Dilgimen A, Moriarty TJ, Chaconas G, Marques A, Krawetz R, Mody CH, Kubes P. 2014. Invariant natural killer T cells act as an extravascular cytotoxic barrier for joint-invading Lyme Borrelia. Proc Natl Acad Sci USA
111:13936–13941. 10.1073/pnas.1404769111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1404769111</ArticleId>
            <ArticleId IdType="pmc">PMC4183287</ArticleId>
            <ArticleId IdType="pubmed">25205813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kinjo Y, Tupin E, Wu D, Fujio M, Garcia-Navarro R, Benhnia MR-E-I, Zajonc DM, Ben-Menachem G, Ainge GD, Painter GF, Khurana A, Hoebe K, Behar SM, Beutler B, Wilson IA, Tsuji M, Sellati TJ, Wong C-H, Kronenberg M. 2006. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol
7:978–986. 10.1038/ni1380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni1380</ArticleId>
            <ArticleId IdType="pubmed">16921381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tupin E, Benhnia MR-E-I, Kinjo Y, Patsey R, Lena CJ, Haller MC, Caimano MJ, Imamura M, Wong C-H, Crotty S, Radolf JD, Sellati TJ, Kronenberg M. 2008. NKT cells prevent chronic joint inflammation after infection with Borrelia burgdorferi. Proc Natl Acad Sci USA
105:19863–19868. 10.1073/pnas.0810519105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0810519105</ArticleId>
            <ArticleId IdType="pmc">PMC2604993</ArticleId>
            <ArticleId IdType="pubmed">19060201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olson CM, Bates TC, Izadi H, Radolf JD, Huber SA, Boyson JE, Anguita J. 2009. Local production of IFN-gamma by invariant NKT cells modulates acute Lyme carditis. J Immunol
182:3728–3734. 10.4049/jimmunol.0804111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.0804111</ArticleId>
            <ArticleId IdType="pmc">PMC2679988</ArticleId>
            <ArticleId IdType="pubmed">19265151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar H, Belperron A, Barthold SW, Bockenstedt LK. 2000. Cutting edge: CD1d deficiency impairs murine host defense against the spirochete, Borrelia burgdorferi. J Immunol
165:4797–4801. 10.4049/jimmunol.165.9.4797.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.165.9.4797</ArticleId>
            <ArticleId IdType="pubmed">11046002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katchar K, Drouin EE, Steere AC. 2013. Natural killer cells and natural killer T cells in Lyme arthritis. Arthritis Res Ther
15:R183. 10.1186/ar4373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/ar4373</ArticleId>
            <ArticleId IdType="pmc">PMC3978756</ArticleId>
            <ArticleId IdType="pubmed">24286535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Godfrey DI, Uldrich AP, McCluskey J, Rossjohn J, Moody DB. 2015. The burgeoning family of unconventional T cells. Nat Immunol
16:1114–1123. 10.1038/ni.3298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.3298</ArticleId>
            <ArticleId IdType="pubmed">26482978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Looringh van Beeck FA, Zajonc DM, Moore PF, Schlotter YM, Broere F, Rutten VPMG, Willemse T, Van Rhijn I. 2008. Two canine CD1a proteins are differentially expressed in skin. Immunogenetics
60:315–324. 10.1007/s00251-008-0297-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00251-008-0297-z</ArticleId>
            <ArticleId IdType="pmc">PMC2668647</ArticleId>
            <ArticleId IdType="pubmed">18488214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Godfrey DI, Stankovic S, Baxter AG. 2010. Raising the NKT cell family. Nat Immunol
11:197–206. 10.1038/ni.1841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.1841</ArticleId>
            <ArticleId IdType="pubmed">20139988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schjaerff M, Keller SM, Affolter VK, Kristensen AT, Moore PF. 2016. Cellular endocytic compartment localization of expressed canine CD1 molecules. Vet Immunol Immunopathol
182:11–21. 10.1016/j.vetimm.2016.08.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vetimm.2016.08.012</ArticleId>
            <ArticleId IdType="pubmed">27863541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schjaerff M, Keller SM, Fass J, Froenicke L, Grahn RA, Lyons L, Affolter VK, Kristensen AT, Moore PF. 2016. Refinement of the canine CD1 locus topology and investigation of antibody binding to recombinant canine CD1 isoforms. Immunogenetics
68:191–204. 10.1007/s00251-015-0889-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00251-015-0889-3</ArticleId>
            <ArticleId IdType="pubmed">26687789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stricker RB, Winger EE. 2001. Decreased CD57 lymphocyte subset in patients with chronic Lyme disease. Immunol Lett
76:43–48. 10.1016/S0165-2478(00)00316-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-2478(00)00316-3</ArticleId>
            <ArticleId IdType="pubmed">11222912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marques A, Brown MR, Fleisher TA. 2009. Natural killer cell counts are not different between patients with post-Lyme disease syndrome and controls. Clin Vaccine Immunol
16:1249–1250. 10.1128/CVI.00167-09.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/CVI.00167-09</ArticleId>
            <ArticleId IdType="pmc">PMC2725528</ArticleId>
            <ArticleId IdType="pubmed">19515868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strle K, Sulka KB, Pianta A, Crowley JT, Arvikar SL, Anselmo A, Sadreyev R, Steere AC. 2017. T-helper 17 cell cytokine responses in Lyme disease correlate with Borrelia burgdorferi antibodies during early infection and with autoantibodies late in the illness in patients with antibiotic-refractory Lyme arthritis. Clin Infect Dis
64:930–938. 10.1093/cid/cix002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/cix002</ArticleId>
            <ArticleId IdType="pmc">PMC5850331</ArticleId>
            <ArticleId IdType="pubmed">28077518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gross DM, Steere AC, Huber BT. 1998. T helper 1 response is dominant and localized to the synovial fluid in patients with Lyme arthritis. J Immunol
160:1022–1028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9551943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strle K, Shin JJ, Glickstein LJ, Steere AC. 2012. Association of a Toll-like receptor 1 polymorphism with heightened Th1 inflammatory responses and antibiotic-refractory Lyme arthritis. Arthritis Rheum
64:1497–1507. 10.1002/art.34383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.34383</ArticleId>
            <ArticleId IdType="pmc">PMC3338893</ArticleId>
            <ArticleId IdType="pubmed">22246581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hasmim M, Khalife N, Zhang Y, Doldur M, Visentin G, Terry S, Giron-Michel J, Tang R, Delhommeau F, Dulphy N, Bourhis J-H, Louache F, Chouaib S. 2017. Expression of CD94 by ex vivo-differentiated NK cells correlates with the in vitro and in vivo acquisition of cytotoxic features. Oncoimmunology
6:e1346763. 10.1080/2162402X.2017.1346763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2017.1346763</ArticleId>
            <ArticleId IdType="pmc">PMC5665075</ArticleId>
            <ArticleId IdType="pubmed">29123958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Beneden K, Stevenaert F, De Creus A, Debacker V, De Boever J, Plum J, Leclercq G. 2001. Expression of Ly49E and CD94/NKG2 on fetal and adult NK cells. J Immunol
166:4302–4311. 10.4049/jimmunol.166.7.4302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.166.7.4302</ArticleId>
            <ArticleId IdType="pubmed">11254682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawamura T, Takeda K, Kaneda H, Matsumoto H, Hayakawa Y, Raulet DH, Ikarashi Y, Kronenberg M, Yagita H, Kinoshita K, Abo T, Okumura K, Smyth MJ. 2009. NKG2A inhibits invariant NKT cell activation in hepatic injury. J Immunol
182:250–258. 10.4049/jimmunol.182.1.250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.182.1.250</ArticleId>
            <ArticleId IdType="pmc">PMC2841747</ArticleId>
            <ArticleId IdType="pubmed">19109156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Backstrom E, Kristensson K, Ljunggren HG. 2004. Activation of natural killer cells: underlying molecular mechanisms revealed. Scand J Immunol
60:14–22. 10.1111/j.0300-9475.2004.01475.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.0300-9475.2004.01475.x</ArticleId>
            <ArticleId IdType="pubmed">15238069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iwaszko M, Bogunia-Kubik K. 2011. Clinical significance of the HLA-E and CD94/NKG2 interaction. Arch Immunol Ther Exp (Warsz)
59:353–367. 10.1007/s00005-011-0137-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00005-011-0137-y</ArticleId>
            <ArticleId IdType="pubmed">21800130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schuberth HJ, Kucinskiene G, Chu RM, Faldyna M. 2007. Reactivity of cross-reacting monoclonal antibodies with canine leukocytes, platelets and erythrocytes. Vet Immunol Immunopathol
119:47–55. 10.1016/j.vetimm.2007.06.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vetimm.2007.06.013</ArticleId>
            <ArticleId IdType="pubmed">17643496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Narni-Mancinelli E, Chaix J, Fenis A, Kerdiles YM, Yessaad N, Reynders A, Gregoire C, Luche H, Ugolini S, Tomasello E, Walzer T, Vivier E. 2011. Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor. Proc Natl Acad Sci USA
108:18324–18329. 10.1073/pnas.1112064108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1112064108</ArticleId>
            <ArticleId IdType="pmc">PMC3215049</ArticleId>
            <ArticleId IdType="pubmed">22021440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graves SS, Gyurkocza B, Stone DM, Parker MH, Abrams K, Jochum C, Gallo S, Saad M, Johnson MM, Rosinski SL, Storb R. 2019. Development and characterization of a canine-specific anti-CD94 (KLRD-1) monoclonal antibody. Vet Immunol Immunopathol
211:10–18. 10.1016/j.vetimm.2019.03.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vetimm.2019.03.005</ArticleId>
            <ArticleId IdType="pmc">PMC7048049</ArticleId>
            <ArticleId IdType="pubmed">31084888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu J, Wei M, Mao H, Zhang J, Hughes T, Mitsui T, Park I-k, Hwang C, Liu S, Marcucci G, Trotta R, Benson DM, Caligiuri MA. 2009. CD94 defines phenotypically and functionally distinct mouse NK cell subsets. J Immunol
183:4968–4974. 10.4049/jimmunol.0900907.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.0900907</ArticleId>
            <ArticleId IdType="pmc">PMC2924742</ArticleId>
            <ArticleId IdType="pubmed">19801519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foltz JA, Somanchi SS, Yang Y, Aquino-Lopez A, Bishop EE, Lee DA. 2016. NCR1 expression identifies canine natural killer cell subsets with phenotypic similarity to human natural killer cells. Front Immunol
7:521.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5120128</ArticleId>
            <ArticleId IdType="pubmed">27933061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadad U, Thauland TJ, Martinez OM, Butte MJ, Porgador A, Krams SM. 2015. NKp46 clusters at the immune synapse and regulates NK cell polarization. Front Immunol
6:495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4585260</ArticleId>
            <ArticleId IdType="pubmed">26441997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yasuda N, Masuda K, Tsukui T, Teng A, Ishii Y. 2009. Identification of canine natural CD3-positive T cells expressing an invariant T-cell receptor alpha chain. Vet Immunol Immunopathol
132:224–231. 10.1016/j.vetimm.2009.08.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vetimm.2009.08.002</ArticleId>
            <ArticleId IdType="pubmed">19748683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacomet F, Cayssials E, Basbous S, Levescot A, Piccirilli N, Desmier D, Robin A, Barra A, Giraud C, Guilhot F, Roy L, Herbelin A, Gombert J-M. 2015. Evidence for eomesodermin-expressing innate-like CD8(+) KIR/NKG2A(+) T cells in human adults and cord blood samples. Eur J Immunol
45:1926–1933. 10.1002/eji.201545539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201545539</ArticleId>
            <ArticleId IdType="pubmed">25903796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pita-Lopez ML, Pera A, Solana R. 2016. Adaptive memory of human NK-like CD8(+) T-cells to aging, and viral and tumor antigens. Front Immunol
7:616. 10.3389/fimmu.2016.00616.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2016.00616</ArticleId>
            <ArticleId IdType="pmc">PMC5165258</ArticleId>
            <ArticleId IdType="pubmed">28066426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C, Liu X, Li Z, Chai Y, Jiang Y, Wang Q, Ji Y, Zhu Z, Wan Y, Yuan Z, Chang Z, Zhang M. 2015. CD8(+)NKT-like cells regulate the immune response by killing antigen-bearing DCs. Sci Rep
5:14124. 10.1038/srep14124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep14124</ArticleId>
            <ArticleId IdType="pmc">PMC4569892</ArticleId>
            <ArticleId IdType="pubmed">26369936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barbarin A, Cayssials E, Jacomet F, Nunez NG, Basbous S, Lefèvre L, Abdallah M, Piccirilli N, Morin B, Lavoue V, Catros V, Piaggio E, Herbelin A, Gombert J-M. 2017. Phenotype of NK-like CD8(+) T cells with innate features in humans and their relevance in cancer diseases. Front Immunol
8:316. 10.3389/fimmu.2017.00316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2017.00316</ArticleId>
            <ArticleId IdType="pmc">PMC5366313</ArticleId>
            <ArticleId IdType="pubmed">28396661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Correia MP, Stojanovic A, Bauer K, Juraeva D, Tykocinski L-O, Lorenz H-M, Brors B, Cerwenka A. 2018. Distinct human circulating NKp30(+)FcepsilonRIgamma(+)CD8(+) T cell population exhibiting high natural killer-like antitumor potential. Proc Natl Acad Sci USA
115:E5980–E5989.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6042091</ArticleId>
            <ArticleId IdType="pubmed">29895693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, Hayakawa Y. 2005. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med
201:1973–1985. 10.1084/jem.20042280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20042280</ArticleId>
            <ArticleId IdType="pmc">PMC1364507</ArticleId>
            <ArticleId IdType="pubmed">15967825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coquet JM, Kyparissoudis K, Pellicci DG, Besra G, Berzins SP, Smyth MJ, Godfrey DI. 2007. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol
178:2827–2834. 10.4049/jimmunol.178.5.2827.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.178.5.2827</ArticleId>
            <ArticleId IdType="pubmed">17312126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ngai H, Tian G, Courtney AN, Ravari SB, Guo L, Liu B, Jin J, Shen ET, Di Pierro EJ, Metelitsa LS. 2018. IL-21 selectively protects CD62L(+) NKT cells and enhances their effector functions for adoptive immunotherapy. J Immunol
201:2141–2153. 10.4049/jimmunol.1800429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1800429</ArticleId>
            <ArticleId IdType="pmc">PMC6143411</ArticleId>
            <ArticleId IdType="pubmed">30111631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu SM, King C. 2013. IL-21-producing Th cells in immunity and autoimmunity. J Immunol
191:3501–3506. 10.4049/jimmunol.1301454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1301454</ArticleId>
            <ArticleId IdType="pubmed">24058193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown CR, Reiner SL. 1999. Experimental Lyme arthritis in the absence of interleukin-4 or gamma interferon. Infect Immun
67:3329–3333. 10.1128/IAI.67.7.3329-3333.1999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.67.7.3329-3333.1999</ArticleId>
            <ArticleId IdType="pmc">PMC116514</ArticleId>
            <ArticleId IdType="pubmed">10377109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma Y, Sturrock A, Weis JJ. 1991. Intracellular localization of Borrelia burgdorferi within human endothelial cells. Infect Immun
59:671–678. 10.1128/iai.59.2.671-678.1991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/iai.59.2.671-678.1991</ArticleId>
            <ArticleId IdType="pmc">PMC257809</ArticleId>
            <ArticleId IdType="pubmed">1987083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Girschick HJ, Huppertz HI, Russmann H, Krenn V, Karch H. 1996. Intracellular persistence of Borrelia burgdorferi in human synovial cells. Rheumatol Int
16:125–132. 10.1007/BF01409985.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF01409985</ArticleId>
            <ArticleId IdType="pubmed">8893378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Livengood JA, Gilmore
RD, Jr.. 
2006. Invasion of human neuronal and glial cells by an infectious strain of Borrelia burgdorferi. Microbes Infect
8:2832–2840. 10.1016/j.micinf.2006.08.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.micinf.2006.08.014</ArticleId>
            <ArticleId IdType="pubmed">17045505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chmielewski T, Tylewska-Wierzbanowska S. 2010. Interactions between Borrelia burgdorferi and mouse fibroblasts. Pol J Microbiol
59:157–160. 10.33073/pjm-2010-024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.33073/pjm-2010-024</ArticleId>
            <ArticleId IdType="pubmed">21033577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petnicki-Ocwieja T, Kern A. 2014. Mechanisms of Borrelia burgdorferi internalization and intracellular innate immune signaling. Front Cell Infect Microbiol
4:175. 10.3389/fcimb.2014.00175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcimb.2014.00175</ArticleId>
            <ArticleId IdType="pmc">PMC4266086</ArticleId>
            <ArticleId IdType="pubmed">25566512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown WC. 2012. Adaptive immunity to Anaplasma pathogens and immune dysregulation: implications for bacterial persistence. Comp Immunol Microbiol Infect Dis
35:241–252. 10.1016/j.cimid.2011.12.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cimid.2011.12.002</ArticleId>
            <ArticleId IdType="pmc">PMC3327808</ArticleId>
            <ArticleId IdType="pubmed">22226382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Appel MJ, Allan S, Jacobson RH, Lauderdale TL, Chang YF, Shin SJ, Thomford JW, Todhunter RJ, Summers BA. 1993. Experimental Lyme disease in dogs produces arthritis and persistent infection. J Infect Dis
167:651–664. 10.1093/infdis/167.3.651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/infdis/167.3.651</ArticleId>
            <ArticleId IdType="pubmed">8440936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levy SA, O'Connor TP, Hanscom JL, Shields P, Lorentzen L, Dimarco AA. 2008. Quantitative measurement of C6 antibody following antibiotic treatment of Borrelia burgdorferi antibody-positive nonclinical dogs. Clin Vaccine Immunol
15:115–119. 10.1128/CVI.00340-07.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/CVI.00340-07</ArticleId>
            <ArticleId IdType="pmc">PMC2223868</ArticleId>
            <ArticleId IdType="pubmed">18003819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chandrashekar R, Beall MJ, Thatcher B, Saucier JM, Tyrrell P, Lappin MR. 2017. Serologic responses to peptides of Anaplasma phagocytophilum and Borrelia burgdorferi in dogs infested with wild-caught Ixodes scapularis. Vet J
226:6–11. 10.1016/j.tvjl.2017.06.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tvjl.2017.06.005</ArticleId>
            <ArticleId IdType="pubmed">28911844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goodman JL, Bradley JF, Ross AE, Goellner P, Lagus A, Vitale B, Berger BW, Luger S, Johnson RC. 1995. Bloodstream invasion in early Lyme disease: results from a prospective, controlled, blinded study using the polymerase chain reaction. Am J Med
99:6–12. 10.1016/S0002-9343(99)80097-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9343(99)80097-7</ArticleId>
            <ArticleId IdType="pubmed">7598144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aguero-Rosenfeld ME, Wormser GP. 2015. Lyme disease: diagnostic issues and controversies. Expert Rev Mol Diagn
15:1–4. 10.1586/14737159.2015.989837.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/14737159.2015.989837</ArticleId>
            <ArticleId IdType="pubmed">25482091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang L, Wang J, Schorter L, Nguyen Trong TP, Fell S, Ulrich S, Straubinger RK. 2020. Rapid clearance of Borrelia burgdorferi from the blood circulation. Parasit Vectors
13:191. 10.1186/s13071-020-04060-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13071-020-04060-y</ArticleId>
            <ArticleId IdType="pmc">PMC7171858</ArticleId>
            <ArticleId IdType="pubmed">32312278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glickstein L, Edelstein M, Dong JZ. 2001. Gamma interferon is not required for arthritis resistance in the murine Lyme disease model. Infect Immun
69:3737–3743. 10.1128/IAI.69.6.3737-3743.2001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.69.6.3737-3743.2001</ArticleId>
            <ArticleId IdType="pmc">PMC98381</ArticleId>
            <ArticleId IdType="pubmed">11349038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Widhe M, Jarefors S, Ekerfelt C, Vrethem M, Bergström S, Forsberg P, Ernerudh J. 2004. Borrelia-specific interferon-gamma and interleukin-4 secretion in cerebrospinal fluid and blood during Lyme borreliosis in humans: association with clinical outcome. J Infect Dis
189:1881–1891. 10.1086/382893.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/382893</ArticleId>
            <ArticleId IdType="pubmed">15122525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dame TM, Orenzoff BL, Palmer LE, Furie MB. 2007. IFN-gamma alters the response of Borrelia burgdorferi-activated endothelium to favor chronic inflammation. J Immunol
178:1172–1179. 10.4049/jimmunol.178.2.1172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.178.2.1172</ArticleId>
            <ArticleId IdType="pubmed">17202382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaix J, Tessmer MS, Hoebe K, Fuséri N, Ryffel B, Dalod M, Alexopoulou L, Beutler B, Brossay L, Vivier E, Walzer T. 2008. Cutting edge: priming of NK cells by IL-18. J Immunol
181:1627–1631. 10.4049/jimmunol.181.3.1627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.181.3.1627</ArticleId>
            <ArticleId IdType="pmc">PMC5154249</ArticleId>
            <ArticleId IdType="pubmed">18641298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabry M, Zubiak A, Hood SP, Simmonds P, Arellano-Ballestero H, Cournoyer E, Mashar M, Pockley AG, Lowdell MW. 2019. Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures. PLoS One
14:e0218674. 10.1371/journal.pone.0218674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0218674</ArticleId>
            <ArticleId IdType="pmc">PMC6594622</ArticleId>
            <ArticleId IdType="pubmed">31242243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soloski MJ, Crowder LA, Lahey LJ, Wagner CA, Robinson WH, Aucott JN. 2014. Serum inflammatory mediators as markers of human Lyme disease activity. PLoS One
9:e93243. 10.1371/journal.pone.0093243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0093243</ArticleId>
            <ArticleId IdType="pmc">PMC3989169</ArticleId>
            <ArticleId IdType="pubmed">24740099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leonard WJ, Wan CK. 2016. IL-21 signaling in immunity. F1000Res
5:224. 10.12688/f1000research.7634.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12688/f1000research.7634.1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solaymani-Mohammadi S, Eckmann L, Singer SM. 2019. Interleukin (IL)-21 in inflammation and immunity during parasitic diseases. Front Cell Infect Microbiol
9:401. 10.3389/fcimb.2019.00401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcimb.2019.00401</ArticleId>
            <ArticleId IdType="pmc">PMC6904299</ArticleId>
            <ArticleId IdType="pubmed">31867283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, Johnston J, Madden K, Xu W, West J, Schrader S, Burkhead S, Heipel M, Brandt C, Kuijper JL, Kramer J, Conklin D, Presnell SR, Berry J, Shiota F, Bort S, Hambly K, Mudri S, Clegg C, Moore M, Grant FJ, Lofton-Day C, Gilbert T, Rayond F, Ching A, Yao L, Smith D, Webster P, Whitmore T, Maurer M, Kaushansky K, Holly RD, Foster D. 2000. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature
408:57–63. 10.1038/35040504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35040504</ArticleId>
            <ArticleId IdType="pubmed">11081504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parrish-Novak J, Foster DC, Holly RD, Clegg CH. 2002. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol
72:856–863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12429707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seo H, Jeon I, Kim B-S, Park M, Bae E-A, Song B, Koh C-H, Shin K-S, Kim I-K, Choi K, Oh T, Min J, Min BS, Han YD, Kang S-J, Shin SJ, Chung Y, Kang C-Y. 2017. IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours. Nat Commun
8:15776. 10.1038/ncomms15776.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms15776</ArticleId>
            <ArticleId IdType="pmc">PMC5467212</ArticleId>
            <ArticleId IdType="pubmed">28585539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burgess SJ, Marusina AI, Pathmanathan I, Borrego F, Coligan JE. 2006. IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells. J Immunol
176:1490–1497. 10.4049/jimmunol.176.3.1490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.176.3.1490</ArticleId>
            <ArticleId IdType="pubmed">16424177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golightly M, Thomas J, Volkman D, Dattwyler R. 1988. Modulation of natural killer cell activity by Borrelia burgdorferi. Ann N Y Acad Sci
539:103–111. 10.1111/j.1749-6632.1988.tb31843.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1749-6632.1988.tb31843.x</ArticleId>
            <ArticleId IdType="pubmed">3056196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bi J, Tian Z. 2017. NK cell exhaustion. Front Immunol
8:760. 10.3389/fimmu.2017.00760.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2017.00760</ArticleId>
            <ArticleId IdType="pmc">PMC5487399</ArticleId>
            <ArticleId IdType="pubmed">28702032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Maria A, Fogli M, Costa P, Murdaca G, Puppo F, Mavilio D, Moretta A, Moretta L. 2003. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol
33:2410–2418. 10.1002/eji.200324141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.200324141</ArticleId>
            <ArticleId IdType="pubmed">12938217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sivori S, Pende D, Bottino C, Marcenaro E, Pessino A, Biassoni R, Moretta L, Moretta A. 1999. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol
29:1656–1666. 10.1002/(SICI)1521-4141(199905)29:05&lt;1656::AID-IMMU1656&gt;3.0.CO;2-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1521-4141(199905)29:05&lt;1656::AID-IMMU1656&gt;3.0.CO;2-1</ArticleId>
            <ArticleId IdType="pubmed">10359120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dons'koi BV, Osypchuk DV, Chernyshov VP. 2019. Enumeration of peripheral blood NKp46 positive NK lymphocytes reflects NK cytotoxic activity in vitro. J Immunol Methods
474:112639. 10.1016/j.jim.2019.112639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jim.2019.112639</ArticleId>
            <ArticleId IdType="pubmed">31404551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SEA, Yagita H, Takeda K, van Dommelen SLH, Degli-Esposti MA, Hayakawa Y. 2005. Activation of NK cell cytotoxicity. Mol Immunol
42:501–510. 10.1016/j.molimm.2004.07.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molimm.2004.07.034</ArticleId>
            <ArticleId IdType="pubmed">15607806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diuk-Wasser MA, Vannier E, Krause PJ. 2016. Coinfection by Ixodes tick-borne pathogens: ecological, epidemiological, and clinical consequences. Trends Parasitol
32:30–42. 10.1016/j.pt.2015.09.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pt.2015.09.008</ArticleId>
            <ArticleId IdType="pmc">PMC4713283</ArticleId>
            <ArticleId IdType="pubmed">26613664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nieto NC, Foley JE. 2009. Meta-analysis of coinfection and coexposure with Borrelia burgdorferi and Anaplasma phagocytophilum in humans, domestic animals, wildlife, and Ixodes ricinus-complex ticks. Vector Borne Zoonotic Dis
9:93–102. 10.1089/vbz.2008.0072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/vbz.2008.0072</ArticleId>
            <ArticleId IdType="pubmed">18789001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahachi K, Kontowicz E, Anderson B, Toepp AJ, Lima AL, Larson M, Wilson G, Grinnage-Pulley T, Bennett C, Ozanne M, Anderson M, Fowler H, Parrish M, Saucier J, Tyrrell P, Palmer Z, Buch J, Chandrashekar R, Scorza B, Brown G, Oleson JJ, Petersen CA. 2020. Predominant risk factors for tick-borne co-infections in hunting dogs from the USA. Parasit Vectors
13:247. 10.1186/s13071-020-04118-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13071-020-04118-x</ArticleId>
            <ArticleId IdType="pmc">PMC7218638</ArticleId>
            <ArticleId IdType="pubmed">32404151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esch KJ, Juelsgaard R, Martinez PA, Jones DE, Petersen CA. 2013. Programmed death 1-mediated T cell exhaustion during visceral leishmaniasis impairs phagocyte function. J Immunol
191:5542–5550. 10.4049/jimmunol.1301810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1301810</ArticleId>
            <ArticleId IdType="pmc">PMC3896087</ArticleId>
            <ArticleId IdType="pubmed">24154626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee S-H, Shin D-J, Kim Y, Kim C-J, Lee J-J, Yoon MS, Uong TNT, Yu D, Jung J-Y, Cho D, Jung B-G, Kim S-K, Suh G-H. 2018. Comparison of phenotypic and functional characteristics between canine non-B, non-T natural killer lymphocytes and CD3(+)CD5(dim)CD21(−) cytotoxic large granular lymphocytes. Front Immunol
9:841. 10.3389/fimmu.2018.00841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.00841</ArticleId>
            <ArticleId IdType="pmc">PMC5934500</ArticleId>
            <ArticleId IdType="pubmed">29755462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rabiger FV, Bismarck D, Protschka M, Köhler G, Moore PF, Büttner M, von Buttlar H, Alber G, Eschke M. 2019. Canine tissue-associated CD4+CD8alpha+ double-positive T cells are an activated T cell subpopulation with heterogeneous functional potential. PLoS One
14:e0213597. 10.1371/journal.pone.0213597.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0213597</ArticleId>
            <ArticleId IdType="pmc">PMC6415905</ArticleId>
            <ArticleId IdType="pubmed">30865691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pantelyushin S, Ranninger E, Guerrera D, Hutter G, Maake C, Markkanen E, Bettschart-Wolfensberger R, Rohrer Bley C, Läubli H, Vom Berg J. 2021. Cross-reactivity and functionality of approved human immune checkpoint blockers in dogs. Cancers (Basel)
13:785. 10.3390/cancers13040785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13040785</ArticleId>
            <ArticleId IdType="pmc">PMC7918463</ArticleId>
            <ArticleId IdType="pubmed">33668625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Somanchi SS, Senyukov VV, Denman CJ, Lee DA. 2011. Expansion, purification, and functional assessment of human peripheral blood NK cells. J Vis Exp. 10.3791/2540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3791/2540</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
